The current study has extended these findings to the MPTP/MPP+ model of PD and suggests that prevention of oxidative stress is an important mechanism underlying the protective effect of rosiglitazone, but one that is independent of PPARγ activation. The gene discussed is PPARG; the disease is Parkinson disease.